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TYPE 1 DIABETES MELLITUS (T1DM), a complex genetic disease characterized by the destruction of 
pancreatic islet β-cells, leads to insulin deficiency and, ultimately, hyperglycemia in inflicted 
individuals. The etiology stems from a progressive autoimmune assault, in which macrophages and 
T cells secrete proinflammatory cytokines, such as IL-1β, IFN-γ, and TNF-α, as well as nitric oxide 
(NO), which provoke β-cell death. The latter situation is further aggravated, as remaining β-cells 
produce chemokines, thereby attracting more immune cells and, thus, escalating the inflammatory 
process. Cytokine-mediated cell death proceeds through necrosis or apoptosis and implicates the 
activation of the Jak/Stat and NF-κB signaling pathways. A common downstream target gene of 
these pathways is inducible NO synthase (iNOS), which generates NO, a major effector of β-cell 
death along with reactive oxygen species. Historically, T1DM has been recapitulated in rodents 
with use of diabetogenic agents, such as streptozotocin (STZ) and alloxan, to destroy the β-cell 
mass. In particular, STZ is distinctly taken up by β-cells, inducing DNA alkylation and leading to 
impaired β-cell function and death. In addition, STZ was also found to generate NO species, further 
deteriorating β-cell survival. More than 30 years ago, Okamoto and colleagues demonstrated that 
STZ and alloxan cause cell death by inducing DNA strand breaks and the activation of poly(ADP)-
ribose synthase. This enzyme, also known as poly(ADP)-ribose polymerase-1 (PARP-1), is activated 
by DNA breaks and uses NAD+ to covalently link units of ADP ribose, thereby forming long 
polymers on nuclear acceptor proteins such as histones. This has been suggested to diminish their 
affinity for DNA, opening the site of DNA damage and allowing access to the base excision repair 
machinery. Despite this important role in signaling and facilitating DNA repair, the split functional 
personality of PARP-1 as Mr. Hyde and Dr. Jeckyll is revealed when PARP-1 is hyperactivated. 
Indeed, in an attempt to replenish the NAD+ pool that is being drained by the PARP-1, the cellular 
ATP stores are rapidly exhausted, resulting in energy crisis-induced necrosis. The latter forms the 
basis of the “Okamoto model,” which provides a unifying hypothesis on how hyperactivation of 
PARP-1 leads to impaired β-cell function (insulin biosynthesis and secretion) and, ultimately, death 
in response to chemical insults. In agreement with this model, several independent studies have 
shown that mice lacking PARP-1 were resistant to STZ-mediated β-cell death and to development 
of hyperglycemia. In parallel, PARP-1-deficient mice were found to be extremely resistant to LPS-
induced endotoxic shock as a consequence of a blunted NF-κB-dependent transcription, leading to 
inhibition of iNOS, as well as TNF-α and IFN-γ, expression in macrophages. Thus, PARP-1 not only 
mediates the cytotoxic effect of NO, but it also appears to stimulate inflammation by regulating 
the NF-κB signal transduction pathway. These compelling data led to a large randomized double-
blind, placebo-controlled trial in which pre-T1DM participants recruited from 18 European 
countries, as well as the United States and Canada, were given the PARP-1 inhibitor nicotinamide 
or a placebo. After five years of treatment, the incidence of developing T1DM was identical in both 
groups. These studies highlight the complexity of T1DM and the pitfalls in translating lessons 
learned in animal models of diabetes to human physiology. Indeed, one critical question arises: 
How well does the STZ-induced β-cell death model mimic T1DM? In fact, hyperactivation of PARP-
1 by STZ results in β-cell death through necrosis, while β-cell destruction in T1DM predominantly 
proceeds through a cytokine-mediated apoptosis process. Interestingly, PARP-1 is cleaved and 
inactivated by caspase-3 and -7 in the early phase of apoptosis, suggesting that PARP-1 does not 
participate in this mode of cell death.  
Furthermore, Heller et al., as early as 1995, demonstrated that islets isolated from PARP-1-
deficient mice were as sensitive as control islets to cell lysis by high concentrations of NO and 
reactive oxygen species. These data clearly raise serious doubts about the importance of PARP-1 
as a key actor in β-cell destruction in a setting of T1DM. Thus, although the role of PARP-1 in β-cell 
destruction via necrosis has been irrefutably associated with STZ and in establishing the validity of 
the Okamoto model, its role in cytokine-mediated cell death remains to be fully explored. In this 
issue of the Journal, Andreone et al. address this gap and challenge the Okamoto model by 
demonstrating that PARP-1 does not participate in the deleterious effect of cytokines on islet 
function and, potentially, survival. Indeed, Andreone et al. demonstrate that, similar to control 
islets, PARP-1-deficient islet cells exposed to the proinflammatory cytokines IL-1 and IFN-γ exhibit 
normal activation of the NF-κB signaling pathway, which leads to induction of iNOS expression and 
production of NO. Furthermore, deletion of PARP-1 did not alter IL-1/IFN-γ-mediated 
phosphorylation of Stat-1, indicating that the Jak/Stat signaling pathway implicated in apoptosis is 
activated by cytokines in PARP-1-deficient islets. Using a biochemical assay that measures uptake 
of a neutral red dye within acidic lysosomes, Andreone et al. show that islets lacking PARP-1 are 
resistant to cytokine-mediated cytotoxicity, whereas they remain sensitive to the general 
apoptotic agent staurosporine. As lysosome acidification is an ATP-dependent process, which may 
be preserved in PARP-1-deficient islets due to sustained levels of ATP, Andreone et al. astutely 
used the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay as 
an alternative approach to evaluate cell death. The TUNEL assay is particularly useful, as it reveals 
DNA strand breaks, which are a hallmark of NO-mediated cell death. Consistent with preserved NO 
production, PARP-1-deficient islets exhibited increased TUNEL-positive cells in the presence of 
cytokines to levels similar to those of treated control islets. Consequently, glucose-induced insulin 
secretion was also impaired in PARP-1-lacking islets treated with cytokine. As development of 
T1DM results from an intricate cross talk between immune cells and islets, Andreone et al. also 
assessed whether inflammatory cell signaling was impaired in macrophages derived from PARP-
deficient mice, as previously reported by others. Surprisingly, the NF-κB signaling pathway, as well 
as downstream iNOS activation and NO production, were unaltered in macrophages derived from 
PARP-1 knockout mice that were exposed to cytokines or LPS. A potential explanation for 
discrepancies in results may stem from the fact that previous studies were performed with 
macrophages exposed in vivo to LPS, while Andreone et al. studied naïve macrophages treated in 
vitro with the endotoxin. The work by Andreone et al. demonstrates that, in contrast to STZ-
mediated cell death and the Okamoto model, PARP-1 does not contribute to cytokine-induced β-
cell damage. Furthermore, PARP-1 does not appear to be implicated in the signaling of the 
inflammatory response by macrophages. These results are consistent with the clinical trial 
demonstrating that nicotinamide does not improve onset of T1DM, causing a serious “nick” in the 
Okamoto model. Nonetheless, one question remains to be clearly resolved from the study of 
Andreone et al.: Does PARP-1 deficiency prevent, beyond doubt, islet cell death? Indeed, DNA 
damage was increased in islets from STZ-treated PARP-1-deficient mice, yet these animals did not 
develop hyperglycemia, and islet integrity and function were preserved. It is tempting to speculate 
that PARP-2, which accounts for ∼10% of all PARP activity in mammalian cells), may provide 
sufficient residual activity to repair STZ-mediated DNA damage in PARP-1 knockout mice, thereby 
avoiding β-cell death and development of hyperglycemia. In this context, it is interesting to note 
that PARP-2 was recently shown to be essential for β-cell function and expansion in response to a 
high-fat diet. Unfortunately, the long-term effect of cytokines on β-cell DNA damage and insulin 
secretion was not addressed by Andreone et al., as all experiments were performed within 24 h of 
treatment.  
A key study that could resolve whether PARP-1 deficiency is an asset in protecting β-cells against a 
continuous exposure to proinflammatory cytokines would involve breeding of PARP-1-deficient 
mice to animal models of experimental autoimmune diabetes. This approach could also offer a 
valuable tool to highlight and resolve potential pitfalls associated with the failure of PARP-1 
inhibitors to delay or prevent onset of T1DM in human subjects. Nonetheless, recent findings 
demonstrating the importance of PARP-2 in β-cell function, combined with the apparent 
redundancy of PARP-1 in cytokine-mediated β-cell dysfunction, strongly argue against the use of 
new and more specific PARP inhibitors such as olaparib as novel therapies for the treatment of 
T1DM. 
 
